Mast Cell-ECM Feedback Loop Extension
The mast cell model (Section Mast Cell Activation Dynamics) can be extended to incorporate extracellular matrix (ECM) degradation and fragment generation, creating a positive feedback loop that produces bistability between healthy and degraded connective tissue states. This extension is motivated by the overrepresentation of hypermobile Ehlers-Danlos syndrome in ME/CFS and the role of ECM fragments as mast cell activators. Four coupled ODEs capture the dynamics:
\[ \begin{aligned} \frac{d [\text{MC}_{\text{act}}]}{d t} &= k_\text{MC,0} + k_\text{MC,ECM} \cdot ([\text{ECMfrag}]^2) / (K_\text{ECMfrag}^2 + [\text{ECMfrag}]^2) - k_\text{MC,stab} \cdot [\text{MC}_{\text{act}}] \\ \frac{d [\text{ECM}_{q}]}{d t} &= k_\text{ECM,synth} - k_\text{ECM,deg} \cdot [\text{MMP}] \cdot [\text{ECM}_{q}] \\ \frac{d [\text{MMP}]}{d t} &= k_\text{MMP,MC} \cdot [\text{MC}_{\text{act}}] + k_\text{MMP,inf} \cdot [\text{IL-6}] - k_\text{MMP,clear} \cdot [\text{MMP}] \\ \frac{d [\text{ECMfrag}]}{d t} &= k_\text{ECM,frag} \cdot [\text{MMP}] \cdot [\text{ECM}_{q}] - k_\text{ECM,frag,clear} \cdot [\text{ECMfrag}] \end{aligned} \]
where \([\text{MC}_{\text{act}}]\) is activated mast cell density, \([\text{ECM}_{q}]\) is ECM quality (normalized to healthy baseline), \([\text{MMP}]\) is matrix metalloproteinase activity, and \([\text{ECMfrag}]\) is ECM fragment concentration. The mast cell activation term includes ECM fragment stimulation with squared dependence (cooperative binding to pattern recognition receptors) and stabilization (\(-k_\text{MC,stab}\)). ECM degradation is MMP-dependent with synthesis constant. MMP induction responds to mast cell activation and IL-6. ECM fragments are generated from MMP-mediated ECM cleavage and cleared at constant rate. The key nonlinearity is the ECM fragment → mast cell activation term: as ECM degrades, fragment concentration rises, activating more mast cells, which release histamine, tryptase, and cytokines (including MMP-9 from mast cells), further degrading ECM. This creates a positive feedback loop that, when loop gain exceeds unity, produces bistability: a low-activation healthy state (low \([\text{MC}_{\text{act}}]\), high \([\text{ECM}_{q}]\), low \([\text{ECMfrag}]\)) and a high-activation degraded state (elevated \([\text{MC}_{\text{act}}]\), low \([\text{ECM}_{q}]\), high \([\text{ECMfrag}]\)). The saddle point defines intervention thresholds: small perturbations near the separatrix can switch the system between states, explaining the dramatic symptom flares observed in MCAS patients with connective tissue comorbidity. The model predicts that treatments reducing mast cell activation (cromolyn, antihistamines) or increasing ECM synthesis (specific collagen support, vitamin C) must push the system below the separatrix to achieve durable remission.
Certainty: 0.50. The biochemical links are established: ECM fragments activate mast cells via TLR2/TLR4 (Magadmi et al. 2019), mast cells release MMP-9 and tryptase that degrade ECM, and histamine/tryptase modulate fibroblast ECM synthesis. The bistability prediction requires verification that loop gain in ME/CFS patients exceeds unity, producing distinct attractor basins. The hysteresis width (magnitude of perturbation required to switch states) is patient-specific and depends on baseline repair capacity (\(k_\text{ECM,synth}\)) and fragment clearance rates. Measurement of ECM fragments (e.g., collagen degradation markers), mast cell activation (serum tryptase), and MMP activity in ME/CFS with and without hEDS can calibrate and validate the model.